Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | CCKBR | P32239 | 2/20 | 0.40 |
| ▸ | EGFR | P00533 | 2/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | F10 | P00742 | 1/20 | 0.38 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.36 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.36 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.35 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2605809 | 0.85 | EGFR (0.47) | HSD17B10CCKBREGFRALDH1A1 | |
| SCHEMBL3958089 | 0.85 | EGFR (0.47) | HSD17B10CCKBREGFRALDH1A1 | |
| SCHEMBL3964364 | 0.85 | EGFR (0.47) | HSD17B10CCKBREGFRALDH1A1 | |
| SCHEMBL5500008 | 0.84 | HSD17B10 (0.41) | HSD17B10EGFRSRCF2 | |
| SCHEMBL12115366 | 0.84 | EGFR (0.51) | CCKBREGFRSRC | |
| SCHEMBL13298503 | 0.83 | MTNR1A (0.41) | CCKBREGFRMTNR1AMTNR1B | |
| SCHEMBL8524717 | 0.83 | EGFR (0.47) | CCKBREGFRSRC | |
| SCHEMBL9910178 | 0.82 | CCKBR (0.42) | CCKBREGFRMTNR1AMTNR1BALDH1A1 | |
| SCHEMBL10820393 | 0.81 | CCKBR (0.39) | CCKBRMTNR1AMTNR1B | |
| SCHEMBL6612604 | 0.80 | EGFR (0.52) | HSD17B10EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8377927-B2 | Compositions and methods for treatment of cancer | ARQULE, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-7262215-B2 | N-carbacycle monosubstituted indolocarbazoles as protein kinase inhibitors | NAD AG (DE) | 2007-08-28 | — | — | US | disclosed |
| US-7262215-B2 | N-carbacycle monosubstituted indolocarbazoles as protein kinase inhibitors | NAD AG (DE) | 2007-08-28 | — | — | US | disclosed |
| US-20050075386-A1 | N-carbacycle monosubstituted indolocarbazoles as protein kinase inhibitors | NAD AG (DE) | 2005-04-07 | — | — | US | disclosed |
| EP-1456211-A1 | N-CARBACYCLE MONOSUBSTITUTED INDOLOCARBAZOLES AS PROTEIN KINASE INHIBITORS | Nad AG (DE) | 2004-09-15 | — | — | EP | disclosed |
| WO-2003051887-A1 | N-CARBACYCLE MONOSUBSTITUTED INDOLOCARBAZOLES AS PROTEIN KINASE INHIBITORS | NAD AG (DE) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075386-A1 | N-carbacycle monosubstituted indolocarbazoles as protein kinase inhibitors | PINK1, IRS1, PNCK | HSD17B10 3619/4885CCKBR 1141/4885EGFR 353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.